Skip to content

Study · In vitro (cell-free) · 2003

6 results

[Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum].

Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh

Izvestiia Akademii nauk. Seriia biologicheskaia1 Jul 2003Cited by 1 (Europe PMC)

PMID12942748 (opens in a new tab)PepBankPUB-12942748
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In vitro, epitalon inhibited enkephalin-degrading enzymes from human serum.

    In plain wordsIn lab tests, epitalon blocked enzymes in human serum that break down enkephalin.

    Peptide
    Epitalon
    Outcome
    DecreaseEnkephalin-degrading enzyme inhibition
    Study

    humann: not reported in source

    human serum
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
    1 context sentence
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.
  2. 02LabIn vitro (cell-free)Activity measurement

    In vitro, the IC50 of epitalon for enkephalin-degrading enzymes from human serum was 500 microM.

    In plain wordsIn lab tests, epitalon cut the activity of enkephalin-degrading enzymes in human serum by half at 500 microM.

    Peptide
    Epitalon
    Outcome
    Not applicableIC50 for enkephalin-degrading enzymes
    Study

    humann: not reported in source

    human serum
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    500 microM
    enkephalin-degrading enzymes, human serum

    Source sentences

    Summary
    The dose-inhibitory effect curves for Livagen and Epitalon were plotted; their IC50 equaled 20 and 500 microM, respectively.
    1 context sentence
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.
  3. 03LabIn vitro (cell-free)Activity measurement

    In human serum assays, Livagen inhibited enkephalin-degrading enzymes with an IC50 of 20 microM.

    In plain wordsIn lab tests with human serum, Livagen inhibited enzymes that break down enkephalin.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseSerum enkephalin-degrading enzyme inhibition
    Study

    humann: not reported in source

    Human serum enkephalin-degrading enzymes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    20 microM
    Livagen inhibition of serum enkephalin-degrading enzymes

    Source sentences

    Summary
    The dose-inhibitory effect curves for Livagen and Epitalon were plotted; their IC50 equaled 20 and 500 microM, respectively.
    2 context sentences
    Summary · context
    Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.
  4. 04LabIn vitro (cell-free)Activity measurement

    In human serum assays, Livagen inhibited enkephalin-degrading enzymes more efficiently than puromycin.

    In plain wordsIn lab tests with human serum, Livagen inhibited enkephalin-degrading enzymes more efficiently than puromycin.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseEnkephalin-degrading enzyme inhibition versus puromycin
    Study

    humann: not reported in source

    Human serum enkephalin-degrading enzymes
    Comparator
    Puromycin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen proved to be more efficient also as compared to well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM.
    2 context sentences
    Summary · context
    Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.
  5. 05LabIn vitro (cell-free)Activity measurement

    In human serum assays, Livagen inhibited enkephalin-degrading enzymes more efficiently than leupeptin.

    In plain wordsIn lab tests with human serum, Livagen inhibited enkephalin-degrading enzymes more efficiently than leupeptin.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseEnkephalin-degrading enzyme inhibition versus leupeptin
    Study

    humann: not reported in source

    Human serum enkephalin-degrading enzymes
    Comparator
    Leupeptin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen proved to be more efficient also as compared to well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM.
    2 context sentences
    Summary · context
    Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.
  6. 06LabIn vitro (cell-free)Activity measurement

    In human serum assays, Livagen inhibited enkephalin-degrading enzymes more efficiently than D-PAM.

    In plain wordsIn lab tests with human serum, Livagen inhibited enkephalin-degrading enzymes more efficiently than D-PAM.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseEnkephalin-degrading enzyme inhibition versus D-PAM
    Study

    humann: not reported in source

    Human serum enkephalin-degrading enzymes
    Comparator
    D-PAM
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Livagen proved to be more efficient also as compared to well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM.
    2 context sentences
    Summary · context
    Livagen and Epitalon inhibited enkephalin-degrading enzymes from human serum.
    Summary · context
    Enkephalinase activity was assayed in vitro by the rate of 3H-Leu-enkephalin hydrolysis in the presence of the tested peptides.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 10Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 7 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 17:28 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.